Arbaclofen in fragile X syndrome: results of phase 3 trials

BACKGROUND: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for social avoidance in FXS. METHODS: Two phase 3 placebo-c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Neurodev Disord
Auteurs principaux: Berry-Kravis, Elizabeth, Hagerman, Randi, Visootsak, Jeannie, Budimirovic, Dejan, Kaufmann, Walter E., Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Wang, Paul, Bear, Mark F., Carpenter, Randall L.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467054/
https://ncbi.nlm.nih.gov/pubmed/28616094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-016-9181-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires